{"url_path":"/register/2026-05-19/2026-10010","section_key":"summary","section_title":"Certain Drug Products Containing C-Type Natriuretic Peptide Variants, and Components Thereof; Notice of a Commission Determination Not To Review an Initial Determination Amending the Complaint and Notice of Investigation","topic":"register","document":{"doc_type":"Notice","doc_date":"2026-05-19","source_url":"https://www.federalregister.gov/documents/2026/05/19/2026-10010/certain-drug-products-containing-c-type-natriuretic-peptide-variants-and-components-thereof-notice","accession_number":null,"cik":null,"ticker":null,"issuer_name":null,"edgar_url":null,"primary_entity_key":null,"primary_entity_name":"International Trade Commission"},"word_count":101,"has_tables":false,"body_markdown":"# Certain Drug Products Containing C-Type Natriuretic Peptide Variants, and Components Thereof; Notice of a Commission Determination Not To Review an Initial Determination Amending the Complaint and Notice of Investigation\n\n**Type:** Notice\n**Published:** 2026-05-19\n**Citation:** 91 FR 29169\n**Agencies:** International Trade Commission\n**Source:** https://www.federalregister.gov/documents/2026/05/19/2026-10010/certain-drug-products-containing-c-type-natriuretic-peptide-variants-and-components-thereof-notice\n\n## Abstract\nNotice is hereby given that the U.S. International Trade Commission (\"Commission\") has determined not to review an initial determination (\"ID\") (Order No. 45) of the presiding Chief administrative law judge (\"Chief ALJ\") granting complainant's unopposed motion to amend the complaint and notice of investigation to reflect respondent Ascendis Pharma, Inc.'s corporate name change to Ascendis Pharma, LLC."}